Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. [electronic resource]
Producer: 20160628Description: 200-211 p. digitalISSN:- 1474-5488
- Adenine -- analogs & derivatives
- Adult
- Aged
- Aged, 80 and over
- Anemia -- chemically induced
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Atrial Fibrillation -- chemically induced
- Bendamustine Hydrochloride -- administration & dosage
- Disease Progression
- Disease-Free Survival
- Double-Blind Method
- Female
- Hemorrhage -- chemically induced
- Humans
- Intention to Treat Analysis
- Leukemia, Lymphocytic, Chronic, B-Cell -- drug therapy
- Male
- Middle Aged
- Nausea -- chemically induced
- Neutropenia -- chemically induced
- Piperidines
- Pyrazoles -- administration & dosage
- Pyrimidines -- administration & dosage
- Retreatment
- Rituximab -- administration & dosage
- Thrombocytopenia -- chemically induced
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.